View clinical trials related to Alzheimer Disease.
Filter by:This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.
To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease who has no other disease-modifying treatment options.
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.
From the past research that has been done the investigators have learned that brain cells die & leave a deposit in the brain known as beta-amyloid. Since alzheimer's is a slow acting disease the natural immune system does not respond to this illness so this builds up in the brain. As it builds up it gets into the neurotransmitters in the brain causing more brain cells to die. As these buildups occur dementia sets in due to more of the brain dying & effects normal activity. STUDY WAS CANCELLED Hypnotherapy will be used to do the following things: - Increase the immune system - The immune system will begin to clean up the beta-amyloid buildup - That removes damage cells of the brain - Increase more blood flow to the brain - Allows the active brain cells to be trained to carry out daily activities STUDY WAS CANCELLED